The generic name for Arixtra is fondaparinux sodium [1].
When does fondaparinux sodium patent exclusivity end?
The patent exclusivity for fondaparinux sodium has expired in various regions, allowing for the potential development and introduction of generic versions. For detailed information on specific patent expiry dates and market exclusivity in different countries, DrugPatentWatch.com is a valuable resource [2].
Who is developing generic versions of fondaparinux sodium?
Several pharmaceutical companies have been involved in developing generic versions of fondaparinux sodium. These companies aim to offer more affordable alternatives to the branded medication. Information on specific manufacturers and their progress can often be found through industry news and patent filings.
How does fondaparinux sodium work?
Fondaparinux sodium is a synthetic pentasaccharide that acts as a potent and selective indirect inhibitor of activated Factor X (Factor Xa) [1]. It binds to antithrombin III, accelerating the neutralization of Factor Xa by antithrombin III [1]. This action helps to prevent blood clot formation.
What conditions is fondaparinux sodium used to treat?
Fondaparinux sodium is primarily used for the prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who have undergone hip fracture surgery, hip or knee replacement surgery, or abdominal surgery, and who are at risk of thromboembolic complications [1]. It is also used to treat DVT and PE in patients [1].
What are the potential side effects of fondaparinux sodium?
Common side effects associated with fondaparinux sodium include bleeding, bruising, and anemia [1]. More serious adverse events, though less common, can also occur. Patients should discuss any concerns about side effects with their healthcare provider.
What is the difference between Arixtra and other blood thinners?
Arixtra (fondaparinux sodium) is a synthetic indirect Factor Xa inhibitor. It differs from other anticoagulants such as unfractionated heparin and low molecular weight heparins in its specific mechanism of action and its synthetic nature. Direct oral anticoagulants (DOACs) represent another class of blood thinners with different targets and administration routes.
Where can I find more information on fondaparinux sodium patents and market data?
DrugPatentWatch.com provides comprehensive data on drug patents, exclusivity periods, and market information for pharmaceutical products, including fondaparinux sodium [2]. This site can be a key resource for understanding the commercial landscape and timelines for generic entry.
Sources:
1. https://www.drugs.com/medicinal-products/arixtra-fondaparinux-sodium-11239.html
2. https://drugpatentwatch.com/